Breaking News

Over a month ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Syneos Health, Daiichi Sankyo agree to develop ADC Oncology pipeline » 08:39
05/28/20
05/28
08:39
05/28/20
08:39
SYNH

Syneos Health

$62.37 /

+1.5 (+2.46%)

Daiichi Sankyo announced…

Daiichi Sankyo announced that it has entered into a strategic agreement with Syneos Health. The companies are coming together to form a coalition to accomplish their shared goal of bringing promising cancer therapies to patients as safely, effectively and efficiently as possible. Under the agreement, Syneos Health will provide both strategic and operational solutions for three lead Daiichi Sankyo DXd antibody drug conjugates, or ADC: DS-1062, U3-1402 and DS-8201. The coalition expands a pre-existing relationship between the two companies. The coalition will enable early strategic engagement of Syneos Health teams to inform drug development decision making from the start. Cross-functional teams from both companies will share therapeutic expertise and product development insights to shape study designs and create a clinical delivery process across a portfolio of studies.

ShowHide Related Items >><<
SYNH Syneos Health
$62.37 /

+1.5 (+2.46%)

SYNH Syneos Health
$62.37 /

+1.5 (+2.46%)

04/03/20 Mizuho
Syneos Health price target lowered to $42 from $56 at Mizuho
04/02/20 Credit Suisse
Syneos Health price target lowered to $62 from $72 at Credit Suisse
03/30/20 Goldman Sachs
Syneos Health downgraded to Neutral from Buy at Goldman Sachs
03/17/20 SunTrust
SunTrust cuts price targets across CROs, downgrades MedPace
SYNH Syneos Health
$62.37 /

+1.5 (+2.46%)

SYNH Syneos Health
$62.37 /

+1.5 (+2.46%)

Hot Stocks
Syneos Health initiates cost management strategies » 06:40
04/30/20
04/30
06:40
04/30/20
06:40
SYNH

Syneos Health

$56.66 /

+3.52 (+6.62%)

In light of the current…

In light of the current situation, the company has initiated proactive cost management strategies to enhance its operational and financial flexibility. To minimize the margin impact from the short-term revenue headwinds, the company has taken a number of actions, including the following:accelerated ForwardBound margin enhancement initiative, delayed hiring of non-billable headcount, reduced or eliminated third party costs and non-essential contractors, implemented temporary salary reduction for the Board of Directors, executives, and highly compensated individuals, suspended 401k match, executed voluntary furloughs, and rationalized portfolio of services.

ShowHide Related Items >><<
SYNH Syneos Health
$56.66 /

+3.52 (+6.62%)

04/03/20 Mizuho
Syneos Health price target lowered to $42 from $56 at Mizuho
04/02/20 Credit Suisse
Syneos Health price target lowered to $62 from $72 at Credit Suisse
03/30/20 Goldman Sachs
Syneos Health downgraded to Neutral from Buy at Goldman Sachs
03/17/20 SunTrust
SunTrust cuts price targets across CROs, downgrades MedPace
Earnings
Syneos Health reports Q1 adjusted EPS 68c, consensus 62c » 06:39
04/30/20
04/30
06:39
04/30/20
06:39
SYNH

Syneos Health

$56.66 /

+3.52 (+6.62%)

Reports Q1 revenue…

Reports Q1 revenue $1.16B, consensus $1.14B.

ShowHide Related Items >><<
SYNH Syneos Health
$56.66 /

+3.52 (+6.62%)

04/03/20 Mizuho
Syneos Health price target lowered to $42 from $56 at Mizuho
04/02/20 Credit Suisse
Syneos Health price target lowered to $62 from $72 at Credit Suisse
03/30/20 Goldman Sachs
Syneos Health downgraded to Neutral from Buy at Goldman Sachs
03/17/20 SunTrust
SunTrust cuts price targets across CROs, downgrades MedPace
Conference/Events
Eyeforpharma to hold a virtual conference » 07:53
04/15/20
04/15
07:53
04/15/20
07:53
ABBV

AbbVie

$82.12 /

+4.07 (+5.21%)

, ABEO

Abeona Therapeutics

$2.59 /

+0.175 (+7.25%)

, ALKS

Alkermes

$15.55 /

+0.17 (+1.11%)

, AMGN

Amgen

$226.75 /

+8.46 (+3.88%)

, AMRN

Amarin

$6.38 /

+ (+0.00%)

, AZN

AstraZeneca

$48.71 /

+1.29 (+2.72%)

, BAYRY

Bayer

$0.00 /

+ (+0.00%)

, BIIB

Biogen

$333.55 /

+10.7 (+3.31%)

, CRM

Salesforce

$157.79 /

+5.27 (+3.46%)

, DIS

Disney

$106.00 /

+2.45 (+2.37%)

, ESALY

Eisai

$0.00 /

+ (+0.00%)

, FB

Facebook

$177.92 /

+3.05 (+1.74%)

, GSK

GlaxoSmithKline

$40.38 /

+1.45 (+3.72%)

, GTHX

G1 Therapeutics

$13.08 /

+0.75 (+6.08%)

, LLY

Eli Lilly

$151.17 /

+6.81 (+4.72%)

, MNK

Mallinckrodt

$3.92 /

+0.175 (+4.67%)

, MRK

Merck

$82.86 /

+2.33 (+2.89%)

, MSFT

Microsoft

$173.70 /

+8.19 (+4.95%)

, NVO

Novo Nordisk

$59.81 /

+1.03 (+1.75%)

, NVS

Novartis

$86.25 /

+2.03 (+2.41%)

, OTSKY

Otsuka

$0.00 /

+ (+0.00%)

, PFE

Pfizer

$36.44 /

+1.29 (+3.67%)

, SEPR

Sepracor

$0.00 /

+ (+0.00%)

, SGEN

Seattle Genetics

$123.79 /

+3.77 (+3.14%)

, SNY

Sanofi

$45.96 /

+1.57 (+3.54%)

, SYNH

Syneos Health

$49.67 /

+2.12 (+4.46%)

, TAK

Takeda Pharmaceutical

$16.88 /

+0.18 (+1.08%)

Eyeforpharma Philadelphia…

Eyeforpharma Philadelphia will be held virtually on April 14-17 with webcasts starting at 9 am each day. Webcast Link

ShowHide Related Items >><<
ABBV AbbVie
$82.12 /

+4.07 (+5.21%)

03/30/20 Piper Sandler
CytomX Therapeutics payment for CX-2029 notable milestone, says Piper Sandler
03/26/20 Piper Sandler
Doctor survey shows 'massive' near-term COVID disruption, says Piper Sandler
03/24/20 Wedbush
CytomX Therapeutics upgraded to Outperform at Wedbush
03/23/20 Societe Generale
AbbVie downgraded to Hold from Buy at Societe Generale
ABEO Abeona Therapeutics
$2.59 /

+0.175 (+7.25%)

12/30/19 H.C. Wainwright
Abeona Therapeutics price target lowered to $11 from $15 at H.C. Wainwright
12/20/19 Cantor Fitzgerald
Abeona financing to lessen takeover chartter, says Cantor Fitzgerald
12/10/19 Cantor Fitzgerald
Abeona Therapeutics assumed with a Neutral at Cantor Fitzgerald
08/15/19
Fly Intel: Top five analyst downgrades
ALKS Alkermes
$15.55 /

+0.17 (+1.11%)

02/14/20 JPMorgan
JPMorgan downgrades Alkermes to Neutral into 'relatively quiet' 2020
02/14/20 H.C. Wainwright
Alkermes profitability focus 'underwhelms' for 2020, says H.C. Wainwright
02/14/20 BofA
Alkermes downgraded to Neutral from Buy at BofA
02/14/20 BofA
Alkermes downgraded to Neutral from Buy at BofA
AMGN Amgen
$226.75 /

+8.46 (+3.88%)

04/13/20 Citi
Sharp drop in chemo use negative for Amgen and Coherus, says Citi
03/31/20 Wolfe Research
Amgen initiated with a Peer Perform at Wolfe Research
03/30/20
Fly Intel: Top five analyst upgrades
03/29/20 Raymond James
Raymond James upgrades Amgen to Outperform on limited COVID-19 disruption
AMRN Amarin
$6.38 /

+ (+0.00%)

04/14/20 Roth Capital
Amarin gearing up to push back against ANDA filers ruling, says Roth Capital
04/14/20 Cowen
Amarin price target raised to $10 from $8 at Cowen
04/14/20 Stifel
Amarin 2020 view 'sufficiently conservative' to still be achievable, says Stifel
04/14/20 Jefferies
Amarin's Vascepa launch continues to be one of best in biotech, says Jefferies
AZN AstraZeneca
$48.71 /

+1.29 (+2.72%)

04/13/20 B. Riley FBR
AstraZeneca study halt has positive read-through to Fortress, says B. Riley FBR
02/28/20 Cowen
AstaZeneca pipeline leads to best European idea, says Cowen
01/27/20 William Blair
PhaseBio could see increase to PB2452 addressable market, says William Blair
01/22/20 Liberum
Sanofi downgraded to Hold from Buy at Liberum (earlier)
BAYRY Bayer
$0.00 /

+ (+0.00%)

03/13/20 Goldman Sachs
Bayer price target lowered to EUR 76 from EUR 77 at Goldman Sachs
03/11/20 Deutsche Bank
Deutsche Bank names Bayer as 'Catalyst Call' buy idea
03/04/20 Deutsche Bank
Bayer upgraded to Buy from Hold at Deutsche Bank
12/19/19 BofA
Elanco upgraded to Buy from Neutral at BofA/Merrill
BIIB Biogen
$333.55 /

+10.7 (+3.31%)

03/31/20 Wolfe Research
Biogen initiated with a Peer Perform at Wolfe Research
03/13/20 Jefferies
Large-cap biotech remains good 'defensive zone' for 2020, says Jefferies
02/28/20 William Blair
Biogen deal with Sangamo unlikely to have near-term impact, says William Blair
CRM Salesforce
$157.79 /

+5.27 (+3.46%)

04/01/20 Wedbush
Salesforce removed from Best Ideas List at Wedbush
03/24/20 Wedbush
Microsoft, Alphabet among stocks in Wedbush's Shopping List
03/20/20 Cowen
Salesforce reiterated as a Best idea at Cowen
02/27/20 RBC Capital
Former Salesforce co-CEO Block could end up at Workday, Oracle, says RBC Capital
DIS Disney
$106.00 /

+2.45 (+2.37%)

04/14/20 SunTrust
Roku price target lowered to $110 from $160 at SunTrust
04/14/20 Credit Suisse
Cogent price target raised to $99 from $86 at Credit Suisse
04/13/20 Cowen
Glu Mobile weakness a buying opportunity, says Cowen
04/09/20 Rosenblatt
Disney+ could reach almost 70M subscribers by end of June, says Rosenblatt
ESALY Eisai
$0.00 /

+ (+0.00%)

10/24/19 Nomura Instinet
Eisai upgraded to Buy from Neutral at Nomura Instinet
09/24/19 Jefferies
Eisai initiated with a Buy at Jefferies
09/17/19 Daiwa
Eisai downgraded to Sell from Neutral at Daiwa
08/05/19 Citi
Eisai upgraded to Neutral from Sell at Citi
FB Facebook
$177.92 /

+3.05 (+1.74%)

04/09/20 Loop Capital
Facebook price target lowered to $215 from $245 at Loop Capital
04/08/20 Deutsche Bank
Pinterest update shows Snap could post in-line Q1, says Deutsche Bank
04/07/20 Barclays
Facebook price target lowered to $175 from $260 at Barclays
04/02/20 Rosenblatt
Rosenblatt cuts advertising estimates, says Facebook/Roku/Snap show best upside
GSK GlaxoSmithKline
$40.38 /

+1.45 (+3.72%)

03/11/20 JPMorgan
JPMorgan backs Neutral on GSK after 2019 annual report
01/16/20 Barclays
GlaxoSmithKline downgraded to Underweight from Equal Weight at Barclays
12/16/19 Goldman Sachs
BioMarin, Regeneron among Goldman's six Healthcare 'laggards' for 2020
12/03/19 Morgan Stanley
Morgan Stanley sees high odds of Bluebird trading up after multiple myeloma data
GTHX G1 Therapeutics
$13.08 /

+0.75 (+6.08%)

02/27/20 Wedbush
G1 Therapeutics price target lowered to $55 from $67 at Wedbush
01/21/20 H.C. Wainwright
G1 Therapeutics price target raised to $82 from $72 at H.C. Wainwright
01/07/20 BTIG
G1 Therapeutics price target lowered to $51 from $80 at BTIG
08/08/19 JPMorgan
G1 Therapeutics upgraded to Overweight from Neutral at JPMorgan
LLY Eli Lilly
$151.17 /

+6.81 (+4.72%)

04/09/20 Morgan Stanley
Morgan Stanley downgrades Eli Lilly to Equal Weight with premium near prior peak
04/09/20 Morgan Stanley
Eli Lilly downgraded to Equal Weight from Overweight at Morgan Stanley
03/11/20
Fly Intel: Top five analyst upgrades
03/11/20 Goldman Sachs
Eli Lilly upgraded to Conviction Buy from Buy at Goldman Sachs
MNK Mallinckrodt
$3.92 /

+0.175 (+4.67%)

02/25/20 Stifel
Mallinckrodt clearing path for shares to be revalued, says Stifel
01/22/20 Wells Fargo
Revance, Amphastar named top 2020 Specialty Pharmaceuticals ideas at Wells Fargo
09/10/19 Stifel
Mallinckrodt's sale of BioVectra helps alleviate cash pressure, says Stifel
09/09/19 Stifel
Mallinckrodt price target lowered to $8 from $20 at Stifel
MRK Merck
$82.86 /

+2.33 (+2.89%)

04/06/20 Raymond James
NGM Biopharmaceuticals initiated with a Strong Buy at Raymond James
03/23/20 Mizuho
Merck business disruptions have been modest, says Mizuho
03/02/20 William Blair
Merck results revive fears about Seattle Genetics' Adcetris, says William Blair
02/27/20 Barclays
Merck initiated with an Overweight at Barclays
MSFT Microsoft
$173.70 /

+8.19 (+4.95%)

04/15/20 BofA
Microsoft estimates trimmed after reseller checks at BofA
04/02/20 Piper Sandler
RingCentral videoconference product launch negative for Zoom, says Piper Sandler
03/31/20 Citi
Microsoft price target lowered to $167 from $170 at Citi
03/26/20 Baird
Bandwidth added as a Fresh Pick at Baird
NVO Novo Nordisk
$59.81 /

+1.03 (+1.75%)

03/23/20 UBS
Novo Nordisk upgraded to Buy from Neutral at UBS
03/16/20 BofA
Novo Nordisk upgraded to Buy from Neutral at BofA
01/03/20 Guggenheim
Novo Nordisk downgraded to Neutral on continued insulin headwinds at Guggenheim
01/03/20 Guggenheim
Novo Nordisk downgraded to Neutral from Buy at Guggenheim
NVS Novartis
$86.25 /

+2.03 (+2.41%)

03/26/20 Argus
Alcon upgraded to Buy from Hold at Argus
03/11/20 Morgan Stanley
Novartis upgraded to Equal Weight yesterday at Morgan Stanley
03/10/20 H.C. Wainwright
Novartis' recent R&D day driving interest in Xoma, says H.C. Wainwright
03/10/20 Morgan Stanley
Novartis upgraded to Equal Weight from Underweight at Morgan Stanley
OTSKY Otsuka
$0.00 /

+ (+0.00%)

03/26/20 Citi
Otsuka upgraded to Buy from Neutral at Citi
03/24/20 JPMorgan
Otsuka upgraded to Neutral from Underweight at JPMorgan
12/26/19 Mizuho
Otsuka downgraded to Neutral from Buy at Mizuho
12/09/19 Jefferies
Otsuka initiated with a Buy at Jefferies
PFE Pfizer
$36.44 /

+1.29 (+3.67%)

04/03/20 Canaccord
BioNTech price target raised to $60 from $22 at Canaccord
03/25/20 Piper Sandler
Piper Sandler sees FY20 U.S. sales of Opko's Rayaldee at $52.5M
02/27/20 Standpoint Research
Pfizer upgraded to Buy from Hold at Standpoint Research
02/27/20 Barclays
Pfizer initiated with an Equal Weight at Barclays
SEPR Sepracor
$0.00 /

+ (+0.00%)

SGEN Seattle Genetics
$123.79 /

+3.77 (+3.14%)

04/03/20 Stifel
Stifel says Seattle Genetics FDA talks on EV positive, but not surprising
02/18/20 Barclays
Seattle Genetics downgraded to Equal Weight from Overweight at Barclays
02/18/20 Barclays
Seattle Genetics downgraded to Equal Weight from Overweight at Barclays
SNY Sanofi
$45.96 /

+1.57 (+3.54%)

03/27/20 Roth Capital
Roth Capital highlights Translate Bio's scalable mRNA platform
03/17/20 Barclays
Sanofi upgraded to Equal Weight from Underweight at Barclays
03/11/20 Oppenheimer
Regeneron price target raised to $525 from $450 at Oppenheimer
03/10/20 Goldman Sachs
Sanofi upgraded to Buy from Neutral at Goldman Sachs
SYNH Syneos Health
$49.67 /

+2.12 (+4.46%)

04/03/20 Mizuho
Syneos Health price target lowered to $42 from $56 at Mizuho
04/02/20 Credit Suisse
Syneos Health price target lowered to $62 from $72 at Credit Suisse
03/30/20 Goldman Sachs
Syneos Health downgraded to Neutral from Buy at Goldman Sachs
03/17/20 SunTrust
SunTrust cuts price targets across CROs, downgrades MedPace
TAK Takeda Pharmaceutical
$16.88 /

+0.18 (+1.08%)

03/25/20 Piper Sandler
Piper Sandler backs Overweight on 'well capitalized' Exelixis
03/25/20 Stifel
Molecular Templates initiated with a Buy at Stifel
02/25/20 Stifel
Iovance among 'more interesting' cell therapy takeout candidates, says Stifel
02/12/20 Wells Fargo
Fate Therapeutics price target raised to $34 from $24 at Wells Fargo
Over a quarter ago
Earnings
Syneos Health sees Q1 results 'in line' with previous guidance » 06:58
04/07/20
04/07
06:58
04/07/20
06:58
SYNH

Syneos Health

$40.91 /

+6.74 (+19.72%)

The company said,…

The company said, "During the first quarter of 2020, Syneos Health continued to build on the strong operational and financial performance the company highlighted in its fourth quarter and year-end 2019 earnings announcement on February 20, 2020. As a result, the company expects its aggregate financial results for the first quarter of 2020 to be in line with its previously issued guidance range. During the first quarter of 2020, the company maintained strong new business awards in both Clinical and Commercial Solutions, and did not experience any meaningful cancellations related to COVID-19. Further, the company ended the first quarter with robust pipelines of new business opportunities for both the Clinical and Commercial Solutions segments."

ShowHide Related Items >><<
SYNH Syneos Health
$40.91 /

+6.74 (+19.72%)

04/03/20 Mizuho
Syneos Health price target lowered to $42 from $56 at Mizuho
04/02/20 Credit Suisse
Syneos Health price target lowered to $62 from $72 at Credit Suisse
03/30/20 Goldman Sachs
Syneos Health downgraded to Neutral from Buy at Goldman Sachs
03/17/20 SunTrust
SunTrust cuts price targets across CROs, downgrades MedPace
Earnings
Syneos Health withdraws FY20 guidance » 06:57
04/07/20
04/07
06:57
04/07/20
06:57
SYNH

Syneos Health

$40.91 /

+6.74 (+19.72%)

Syneos said, "The…

Syneos said, "The company currently anticipates that the disruption caused by COVID-19 will impact second quarter revenue and will likely extend into at least the third quarter of 2020, before beginning to recover. Due to this ongoing uncertainty, the company is withdrawing its financial guidance for the year ending December 31, 2020 that was issued on February 20, 2020. The company plans to provide further information on its first quarter 2020 earnings call. In light of the current situation, the company has initiated proactive cost management strategies. These include accelerating the company's ForwardBound margin enhancement initiative of organizational and operating model efficiencies, hiring restrictions, reductions in third-party costs, certain compensation adjustments, and other initiatives. The company has also implemented proactive cash conservation initiatives, including delaying some capital expenditures and locking in lower interest rates on certain variable rate debt. The company remains confident in its liquidity position, which includes cash on hand and access to its revolving credit facility. The company is currently subject to only one financial maintenance covenant on its primary debt facilities, a First Lien Leverage Ratio of 4.5x, which applies through the maturity of these facilities in 2024. As of December 31, 2019, the company's First Lien Leverage Ratio, as calculated in accordance with the terms of these facilities, was 2.63x, and is expected to be safely within the financial maintenance covenant as of March 31, 2020."

ShowHide Related Items >><<
SYNH Syneos Health
$40.91 /

+6.74 (+19.72%)

04/03/20 Mizuho
Syneos Health price target lowered to $42 from $56 at Mizuho
04/02/20 Credit Suisse
Syneos Health price target lowered to $62 from $72 at Credit Suisse
03/30/20 Goldman Sachs
Syneos Health downgraded to Neutral from Buy at Goldman Sachs
03/17/20 SunTrust
SunTrust cuts price targets across CROs, downgrades MedPace
Recommendations
Syneos Health price target lowered to $42 from $56 at Mizuho » 07:38
04/03/20
04/03
07:38
04/03/20
07:38
SYNH

Syneos Health

$35.01 /

-1.095 (-3.03%)

Mizuho analyst Ann Hynes…

Mizuho analyst Ann Hynes lowered the firm's price target on Syneos Health to $42 from $56 and keeps a Neutral rating on the shares. The analyst now estimates COVID-19 will likely have a greater negative impact on the contract research organizations than she originally estimated.

ShowHide Related Items >><<
SYNH Syneos Health
$35.01 /

-1.095 (-3.03%)

04/02/20 Credit Suisse
Syneos Health price target lowered to $62 from $72 at Credit Suisse
03/30/20 Goldman Sachs
Syneos Health downgraded to Neutral from Buy at Goldman Sachs
03/17/20 SunTrust
SunTrust cuts price targets across CROs, downgrades MedPace
02/21/20 Mizuho
Syneos Health price target raised to $67 from $52 at Mizuho
Recommendations
Syneos Health price target lowered to $62 from $72 at Credit Suisse » 07:24
04/02/20
04/02
07:24
04/02/20
07:24
SYNH

Syneos Health

$36.11 /

-3.305 (-8.39%)

Credit Suisse analyst…

Credit Suisse analyst Erin Wilson Wright lowered the firm's price target on Syneos Health to $62 from $72 and keeps an Outperform rating on the shares. While there has been no abnormal level of cancellations coinciding with the pandemic, the analyst notes that sponsors are increasingly delaying patient enrollment and new study starts, consistent with the data she has been tracking from industry constituents and her clinicaltrials.gov analysis. The analyst is also lowering her near-term Q2 EPS to 50c from 87c, reflecting an 18% decline in Q2 top-line growth given anticipated study start-up delays, acknowledging the situation remains fluid.

ShowHide Related Items >><<
SYNH Syneos Health
$36.11 /

-3.305 (-8.39%)

03/30/20 Goldman Sachs
Syneos Health downgraded to Neutral from Buy at Goldman Sachs
03/17/20 SunTrust
SunTrust cuts price targets across CROs, downgrades MedPace
02/21/20 Mizuho
Syneos Health price target raised to $67 from $52 at Mizuho
01/16/20 Baird
Syneos Health price target raised to $74 from $62 at Baird
Downgrade
Syneos Health downgraded to Neutral from Buy at Goldman Sachs » 05:04
03/30/20
03/30
05:04
03/30/20
05:04
SYNH

Syneos Health

$41.41 /

-2.51 (-5.71%)

Goldman Sachs analyst…

Goldman Sachs analyst Robert Jones downgraded Syneos Health to Neutral from Buy with a price target of $45, down from $79. In the context of the uncertainty of the trajectory and length of the COVID-19 outbreak, the analyst prefers clinical names with "more favorable exposure." Jones expects uncertainty around biotech funding to affect sentiment for Syneos and sees a "relatively unfavorable" risk profile for the company.

ShowHide Related Items >><<
SYNH Syneos Health
$41.41 /

-2.51 (-5.71%)

03/17/20 SunTrust
SunTrust cuts price targets across CROs, downgrades MedPace
02/21/20 Mizuho
Syneos Health price target raised to $67 from $52 at Mizuho
01/16/20 Baird
Syneos Health price target raised to $74 from $62 at Baird
01/16/20 KeyBanc
Syneos Health price target raised to $71 from $65 at KeyBanc
Downgrade
SunTrust cuts price targets across CROs, downgrades MedPace » 08:19
03/17/20
03/17
08:19
03/17/20
08:19
MEDP

Medpace

$70.08 /

-7.5 (-9.67%)

, SYNH

Syneos Health

$43.51 /

-8.36 (-16.12%)

, PRAH

PRA Health

$69.01 /

-16.17 (-18.98%)

, IQV

Iqvia

$102.50 /

-16.29 (-13.71%)

, CRL

Charles River

$105.12 /

-23.43 (-18.23%)

, ICLR

Icon

$130.00 /

-20.95 (-13.88%)

SunTrust analyst Sandy…

SunTrust analyst Sandy Draper downgraded Medpace (MEDP) to Sell from Hold with a price target of $46, down from $100 as part of a broader research note on contract research organizations, or CROs. The analyst is also cutting his price target on Syneos Health (SYNH) to $58 from $80, PRA Health Sciences (PRAH) to $89 from $127, IQVIA Holdings (IQV) to $128 from $184, Charles River Labs (CRL) to $124 from $188, and ICON Public (ICLR) to $131 from $182. Draper believes that the clinical trial business will be impacted by COVID-19 for at lease the next two quarters as the pandemic is expected to effect site visits, trial recruitment, study start-ups, and new business awards. The analyst is especially bearish on Medpace due to its customer base, with 70% of its revenue serving small biopharma.

ShowHide Related Items >><<
MEDP Medpace
$70.08 /

-7.5 (-9.67%)

03/17/20 SunTrust
Medpace downgraded to Sell from Hold at SunTrust
02/27/20 Credit Suisse
Medpace price target raised to $105 from $99 at Credit Suisse
02/26/20 SunTrust
Medpace price target raised to $100 from $87 at SunTrust
02/25/20 Credit Suisse
Medpace price target raised to $99 from $91 at Credit Suisse
SYNH Syneos Health
$43.51 /

-8.36 (-16.12%)

02/21/20 Mizuho
Syneos Health price target raised to $67 from $52 at Mizuho
01/16/20 Baird
Syneos Health price target raised to $74 from $62 at Baird
01/16/20 KeyBanc
Syneos Health price target raised to $71 from $65 at KeyBanc
01/06/20 Citi
Citi calls Syneos Health top CRO pick, initiates at Buy
PRAH PRA Health
$69.01 /

-16.17 (-18.98%)

01/10/20 Goldman Sachs
PRA Health downgraded to Neutral from Buy at Goldman Sachs
01/06/20 Citi
PRA Health initiated with a Neutral at Citi
11/14/19 Wolfe Research
PRA Health upgraded to Outperform from Peer Perform at Wolfe Research
09/19/19
Fly Intel: Top five analyst initiations
IQV Iqvia
$102.50 /

-16.29 (-13.71%)

03/11/20 JPMorgan
JPMorgan continues to recommend select exposure to Life Science Tools
03/03/20 Deutsche Bank
Iqvia initiated with a Buy at Deutsche Bank
02/20/20 Morgan Stanley
Veeva set up for 'clean' beat and raise Q4 report, says Morgan Stanley
02/14/20 Piper Sandler
Veeva initiated with an Overweight at Piper Sandler
CRL Charles River
$105.12 /

-23.43 (-18.23%)

03/03/20
Fly Intel: Top five analyst initiations
03/03/20 Deutsche Bank
Charles River initiated with a Buy at Deutsche Bank
02/18/20 Wolfe Research
Charles River upgraded to Outperform from Peer Perform at Wolfe Research
02/12/20 Baird
Charles River price target raised to $185 from $165 at Baird
ICLR Icon
$130.00 /

-20.95 (-13.88%)

03/03/20 Deutsche Bank
Icon initiated with a Hold at Deutsche Bank
02/20/20 Mizuho
Icon price target raised to $194 from $179 at Mizuho
01/27/20 SunTrust
Icon downgraded to Hold from Buy at SunTrust
01/07/20 Wells Fargo
Icon initiated with an Equal Weight at Wells Fargo

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.